Advertisement

Cambridge-based AVEO Pharmaceuticals Inc. and Astellas Pharma Inc., of Tokyo, have formed a development and commercialization deal in which AVEO (Nasdaq: AVEO) will bring in $125 million upfront and up to $1.3 billion in potential milestone payments.

The agreement centers around the development of tivozanib, AVEO’s lead treatment for renal cell carcinoma (RCC), currently in Phase 3 clinical trials.

SOURCE

Advertisement
Advertisement